Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Association of community-level social vulnerability with county-level clinical trial access among ovarian cancer patients.

Created on 23 Sep 2026

Authors

Reed M O'Connor, Jennifer A Sinnott, Caitlin E Meade, Simran A Kanal, David M O'Malley, Floor J Backes, Ashley S Felix, Laura M Chambers

Published in

Gynecologic oncology. Volume 213. Pages 95-101. Sep 22, 2026. Epub Sep 22, 2026.

Abstract

Clinical trials are essential to therapeutic advancement, yet access to trials in ovarian cancer may not be equitably distributed. This study evaluated associations between community-level social vulnerability and county-level availability of interventional ovarian cancer clinical trials in the United States.
U.S.-based ovarian cancer clinical trials (2008-2021) identified from the Aggregate Analysis of ClinicalTrials.gov database were aggregated by county and year. Trial availability was defined as ≥1 open interventional trial in a given county-year. County-level availability was linked to the Centers for Disease Control and Prevention Social Vulnerability Index (SVI) and to ovarian cancer cases (diagnosed between 2008 and 2021) from the Surveillance, Epidemiology, and End Results Program. Multivariable logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) for associations between high social vulnerability (SVI ≥90th percentile) and trial availability, adjusting for patient-level factors.
Among 70,486 ovarian cancer patients, 82% resided in counties with available trials during their year of diagnosis. Trial availability increased over time but was concentrated in higher-income, non-rural counties. In multivariable analysis, residence in highly socially vulnerable counties was associated with significantly lower odds of trial availability (OR 0.28, 95% CI 0.21-0.37).
County-level social vulnerability is associated with lower ovarian cancer clinical trial availability. These findings highlight structural inequities in clinical trial infrastructure and support that strategies to expand trial access in socially vulnerable communities are needed.

PMID:
42771918
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement